_asco-2023-highlights-and-analysis.jpg "ASCO 2023: Highlights and analysis from olaparib prostate cancer Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 28 min 40 sec
✓ Published: 06-Jun-2023
✓ Published: 06-Jun-2023
Description:
Associate Prof Bishal Gyawali discusses several presentations that on topics ranging from adjuvant treatments, neo-adjuvant treatments and supportive care, across a range of cancer types. He concludes by giving his opinion on issues with drug approval. nnThe presentations referred to are:nn1.Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC)n2.Phase III NATALEE trial of riboci
Associate Prof Bishal Gyawali discusses several presentations that on topics ranging from adjuvant treatments, neo-adjuvant treatments and supportive care, across a range of cancer types. He concludes by giving his opinion on issues with drug approval. nnThe presentations referred to are:nn1.Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC)n2.Phase III NATALEE trial of riboci
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_olaparib-zytiga-for-metastatic-castrate-resistant-prostate-cancer-124-learn-about-clinical-trials.webp "Prostate Cancer Research Institute")
⏲ 3 minutes 48 seconds 👁 2.1K
_highlights-from-asco-2019.webp "Assistant Prof Bishal Gyawali and Monique Biryiana speak at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the highlights from this year's conference. nnAssistant Prof Gyawali discusses several presentations that address topics ranging from racial disparities, accelerated drug approvals and the importance of assessing overall survival in clinical trials. nnThe presentations that he refer to are: nnAffordable Care Act (ACA) Medicaid expansion impact on racial dispariti")
_the-benefits-of-177lu-psma-617-plus-olaparib-for-prostate-cancer.webp "VJOncology")
_olaparib-and-keytruda-for-advanced-prostate-cancer-124-124-learn-about-clinical-trials.webp "Prostate Cancer Research Institute")
⏲ 5 minutes 14 seconds 👁 1.6K
_parpi-olaparib-for-the-targeted-treatment-of-metastatic-prostate-cancer.webp "Vall d'Hebron Institute of Oncology - VHIO")
_parp-inhibitors-for-metastatic-hormone-sensitive-prostate-cancer.webp "VJOncology")
_asco-2018-novel-treatment-strategies-in-prostate-cancer-therapeutics.webp "Dr Neal Shore speaks to Prof Karim Fizazi about the changing landscape of treatments for prostate cancer, discussing immunotherapies, PARP inhibitors and PSMA testing as future targets and treatments.nnDr Fizazi highlights that anti-PD1 treatment (pembrolizumab) may provide benefit for metastatic castration resistant patients following antiandrogen treatment (5 of the 28 patients in the trial had a PSA decline of50%). nnTrials building on immune checkpoint therapies with novel combinations to")
_the-propel-clinical-trial-exploring-olaparib-plus-abiraterone-in-mcrpc.webp "VJOncology")
_olaparib-zytiga-for-metastatic-castrate-resistant-prostate-cancer-124-learn-about-clinical-trials.jpg)
_highlights-from-asco-2019.jpg)
_the-benefits-of-177lu-psma-617-plus-olaparib-for-prostate-cancer.jpg)
_olaparib-and-keytruda-for-advanced-prostate-cancer-124-124-learn-about-clinical-trials.jpg)
_parpi-olaparib-for-the-targeted-treatment-of-metastatic-prostate-cancer.jpg)
_parp-inhibitors-for-metastatic-hormone-sensitive-prostate-cancer.jpg)
_asco-2018-novel-treatment-strategies-in-prostate-cancer-therapeutics.jpg)
_the-propel-clinical-trial-exploring-olaparib-plus-abiraterone-in-mcrpc.jpg)
![[+]](/images/menu.gif){kind=small}